DGAP-News: MagForce AG Announces Financial Results for the Fiscal Year 2021 and Operational Highlights
In late 2021, MagForce USA obtained FDA approval to utilize the commercial protocol for the ongoing clinical trial.
- In late 2021, MagForce USA obtained FDA approval to utilize the commercial protocol for the ongoing clinical trial.
- Based on these new developments, MagForce USA will be in a stronger financial position to complete the transition to the market.
- MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
- The results actually achieved by MagForce AG may substantially differ from these forward-looking statements.